coiled-coil domain containing 152Genealiases: CH5400 · LIST
Q-omics provides the consensus-scored CCDC152 profile across patient tissues and cancer cell-line models. CCDC152 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CCDC152 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, CCDC152 RNA expression shows 16,835 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, COAD, and UVM as cancer lineages where CCDC152 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC152 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC152 survival associations across molecular data types. CCDC152 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC152 RNA expression–survival associations across cancer types. High CCDC152 expression shows unfavorable associations in STAD and BLCA, but favorable associations in HNSC, KIRC, LUAD and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CCDC152 RNA expression.
This table summarizes CCDC152 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CCDC152. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC152 shows lower tumor expression in COAD, LUAD, THCA, KIRP, LUSC and READ. The COAD box plot shows higher CCDC152 RNA expression in normal versus tumor tissue (log2 FC = −1.832, t-test p < 0.001).
This table shows molecular features associated with CCDC152 in patient tissues and cancer cell lines. In patient samples, CCDC152 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC152 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
